Abstract
The subclassification of α- and β-adrenoceptors has resulted in many opportunities for drug discovery. Important adrenoceptor targets include β2-agonists as bronchodilators, β1 or β1/β2 antagonists as antihypertensives, centrally acting α2-agonists for a variety of applications and α1-antagonists for hypertension and benign prostatic hyperplasia. The pharmacology and nomenclature of 9 adrenoceptors is now established, with α1, α2 and β-adrenoceptors being divided into three subtypes each. It is unlikely that additional discrete adrenoceptor sequences will be identified; however the presence of “affinity states” can give rise to tissue specific differences in pharmacology for a specific subtype. Polymorphisms and splice variants of adrenoceptors continue to be identified; in some cases these modifications can affect pharmacological characteristics and could influence the efficacy of adrenoceptor-targeted therapy. Selective antagonists are now available of all 9 adrenoceptor subtypes. Although these will not all have therapeutic application, the availability of improved pharmacologic tools could lead to the identification of new adrenoceptor targets.
Keywords: Uroselectivity, receptor polymorphism, splice variant, α1L-adrenoceptor, β4-adrenoceptor
Current Topics in Medicinal Chemistry
Title: Subclassification and Nomenclature of α- and β-Adrenoceptors
Volume: 7 Issue: 2
Author(s): J. Paul Hieble
Affiliation:
Keywords: Uroselectivity, receptor polymorphism, splice variant, α1L-adrenoceptor, β4-adrenoceptor
Abstract: The subclassification of α- and β-adrenoceptors has resulted in many opportunities for drug discovery. Important adrenoceptor targets include β2-agonists as bronchodilators, β1 or β1/β2 antagonists as antihypertensives, centrally acting α2-agonists for a variety of applications and α1-antagonists for hypertension and benign prostatic hyperplasia. The pharmacology and nomenclature of 9 adrenoceptors is now established, with α1, α2 and β-adrenoceptors being divided into three subtypes each. It is unlikely that additional discrete adrenoceptor sequences will be identified; however the presence of “affinity states” can give rise to tissue specific differences in pharmacology for a specific subtype. Polymorphisms and splice variants of adrenoceptors continue to be identified; in some cases these modifications can affect pharmacological characteristics and could influence the efficacy of adrenoceptor-targeted therapy. Selective antagonists are now available of all 9 adrenoceptor subtypes. Although these will not all have therapeutic application, the availability of improved pharmacologic tools could lead to the identification of new adrenoceptor targets.
Export Options
About this article
Cite this article as:
Hieble J. Paul, Subclassification and Nomenclature of α- and β-Adrenoceptors, Current Topics in Medicinal Chemistry 2007; 7 (2) . https://dx.doi.org/10.2174/156802607779318172
DOI https://dx.doi.org/10.2174/156802607779318172 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Respiratory Failure in Cancer Patients: Non-Infectious Complications of Antineoplastic Agents for Solid Tumors
Current Respiratory Medicine Reviews The Genetics of Small-Vessel Disease
Current Medicinal Chemistry Regulation of Oxidative Stress and Cardioprotection in Diabetes Mellitus
Current Cardiology Reviews The Accuracy of Self-Reported Hypertension: A Systematic Review and Meta-Analysis
Current Hypertension Reviews Pentoxifylline Alleviates Proteinuria in Fructose Model of Metabolic Syndrome
Letters in Drug Design & Discovery Bicyclic 6 + 6 Systems: Advances in the Chemistry of Heterocyclic Compounds Incorporated Pyrimido[1,2-a]Pyrimidine Skeleton
Mini-Reviews in Organic Chemistry Potential Role of Endothelin in Early Vascular Aging
Current Hypertension Reviews Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice
Current Medicinal Chemistry Colloidal and Pharmacological Activity of Albumin in Clinical Fluid Management:Recent Developments
Current Drug Therapy Monocytes, Macrophages and Other Inflammatory Mediators of Abdominal Aortic Aneurysm
Current Pharmaceutical Design Current Opinion in the Pharmaceutical Management of Irritable and Inflammatory Bowel Diseases: Role of ATP
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Rifaximin: An Antibiotic with Important Biologic Effects
Mini-Reviews in Medicinal Chemistry The Importance of Reendothelialization After Arterial Injury
Current Pharmaceutical Design Acute Kidney Injury in Pediatric Heart Failure
Current Cardiology Reviews Melanin-Concentrating Hormone as a Metabolic and Cognitive Regulatory Factor
Current Medicinal Chemistry - Central Nervous System Agents Emerging Targeted Therapies in Metastatic Renal Cell Carcinoma
Current Clinical Pharmacology Substance P Prevents Vascular Endothelial Dysfunction in Metastatic Breast Carcinoma
Protein & Peptide Letters The Essential Role of Primary Caregiver in Early Detection of Familial Hypercholesterolemia and Cardiovascular Prevention
Current Pediatric Reviews The Role of Pericytes in Neurovascular Unit: Emphasis on Stroke
Current Drug Targets